Geron (GERN) Rips Higher On Exclusive Stem Cell Deal With GE Healthcare
Up)
Geron Corporation (Nasdaq: GERN) is up 30% in the lat 5 minutes after announcing an exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells with GE Healthcare.
Financial terms are not being disclosed, but traders view the news a very positive.
Financial terms are not being disclosed, but traders view the news a very positive.
You May Also Be Interested In
- OmniVision (OVTI) Volatility Up on Move Lower
- Bill Gross Thinks China is the Real Elephant in the Room
- Morgan Stanley (MS) Shares Pressured on Questionable Facebook (FB) Tactics; Hits Fresh 6-Month Low
Create E-mail Alert Related Categories
Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
